Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS

Cathie Wood's ARK ETFs strategically adjusted holdings on July 8, 2025, demonstrating continued conviction in gene-editing by acquiring 102,806 shares of CRISPR Therapeutics (CRSP) valued at $5.26 million, alongside a follow-on investment in Beam Therapeutics (BEAM). Concurrently, ARK significantly reduced positions by selling 62,307 shares of 908 Devices (MASS) for nearly $399,387 and 20,813 shares of Roku (ROKU) for approximately $1.83 million, signaling a strategic shift away from these companies and providing insights into ARK's evolving focus within disruptive innovation.

Analysis

ARK Invest's trading activity on July 8, 2025, signals a deliberate strategic reallocation within its disruptive technology-focused ETFs. The firm reinforced its conviction in the gene-editing sector through a significant acquisition of 102,806 shares in CRISPR Therapeutics (CRSP) for approximately $5.26 million and a tactical follow-on purchase in Beam Therapeutics (BEAM). These buys indicate a deepening bullish stance on genomic therapies. Conversely, ARK continued its systematic reduction of exposure to other holdings, divesting 62,307 shares of 908 Devices (MASS) for nearly $399,387 and 20,813 shares of Roku (ROKU) for $1.83 million. The consistent selling in both MASS and ROKU over the past week suggests a strategic pivot away from these specific names, reflecting a potential reassessment of their long-term growth narratives relative to opportunities elsewhere in the portfolio. These fund flows provide a clear signal of where ARK is concentrating its capital for future growth.

Key Decisions for Investors

• Given ARK's significant and continued accumulation in CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM), investors aligned with a high-growth, high-risk mandate should view these fund flows as a strong bullish signal on the gene-editing sector.
• The persistent selling of Roku (ROKU) and 908 Devices (MASS) by a key thematic investor warrants caution; current holders should re-evaluate their investment thesis and monitor for further institutional selling pressure that could impact share prices.
• Consider these trades as a broader indicator of a strategic rotation within innovation-focused portfolios, potentially favoring deep-science biotech over digital media hardware and certain life science tools for near-term capital allocation.